Synthesis of potential metabolites of (S)-(-)-bromofosfamide

Pharmazie

Volumn 59, Issue 9, 2004, Pages 668-672

  Misiura, Konrad ^a  

^a CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 BROMOETHYL) N (2 CHLOROETHYL)TETRAHYDRO 2H 1,3,2 OXAZAPHOSPHORIN 2 AMINE 2,4 DIOXIDE; 3 (2 BROMOETHYL)TETRAHYDRO 2H 1,3,2 OXAZAPHOSPHORIN 2 AMINE 2 OXIDE; ANTINEOPLASTIC AGENT; BROMINE DERIVATIVE; BROMOFOSFAMIDE; DRUG METABOLITE; IFOSFAMIDE; N (2 CHLOROETHYL)TETRAHYDRO 2H 1,3,2 OXAZAPHOSPHORRIN 2 AMINE 2 OXIDE; O (3 CARBOXYPROPYL) N (2 BROMOETHYL) N' (2 CHLOROETHYL)PHOSPHORODIAMIDATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG HYDROXYLATION; DRUG STRUCTURE; DRUG SYNTHESIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POLAND; REACTION ANALYSIS; THIN LAYER CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; CHROMATOGRAPHY, THIN LAYER; IFOSFAMIDE; MAGNETIC RESONANCE SPECTROSCOPY; STEREOISOMERISM;

EID: 4644281439     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Advani SH (1998) The role of ifosfamide in paediatric cancer. Aust New Zealand J Med 28: 410-413.
2. Bielejewska A, Sinibaldi M, Grynkiewicz G, Kutner A (1999) HPLC separation of enantiomers of bromofosfamide and its metabolites using a chiral stationary phase. Pharm Pharmacol Commun 5: 537-539.
3. Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38: 291-304.
4. Hladon B, Sloderbach A, Laskowska H (1997) Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication. Pol J Pharmacol 49: 127-136.
5. Karolak-Wojciechowska J, Wieczorek M, Grynkiewicz G, Kutner A (1999) Crystal and molecular structure of (-)-(S)- and (+)-(R)-bromofosfamide. Pol J Chem 73: 1877-1885.
6. Kerbusch T, de Kraker J, Keizer J, van Putten JWG, Groen HJM, Jansen RLH, Schellens JHM, Beijnen JH (2001) Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40: 41-62.
7. Kobylinska K, Kobylinska M, Sobik B (2001a) Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice. Arzneim-Forsch/Drug Res 51: 596-599.
8. Kobylinska K, Koralewski P, Sobik B, Gasiorek M, Kobylinska M (2001b) Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients. Arzneim-Forsch/Drug Res 51: 600-603.
9. Misiura K, Pankiewicz K, Stec WJ, Jarman M (1981) The synthesis of enantiomers of 4-ketocyclophosphamide. Experientia 37: 216-217.
10. Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z, Utracka B (1983) Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26: 674-679.
11. Misiura K, Kinas RW, Stec WJ, Kusnierczyk H, Radzikowski C, Sonoda A (1988) Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) Group. J Med Chem 31: 226-230.
12. Misiura K, Kinas RW, Kusnierczyk H, Radzikowski C, Stec WJ (2001) (S)-(-)-bromofosfamide (CBM-11): synthesis and antitumour activity and toxicity in mice. Anti-Cancer Drugs 12: 453-458.
13. Misiura K, Szymanowicz D, Kusnierczyk H, Wietrzyk J, Opolski A (2002) Synthesis and antitumour activity of stereoisomers of 4-hydroperoxy derivatives of ifosfamide and its bromo analogue. Farmaco 57: 315-319.
14. 31P NMR spectroscopy. Arzneim-Forsch/Drug Res. 53: 372-377.
15. 4-crown ether chem Lett 173-174.
16. O'Byrne K, Steward WP (1999) The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 56: 13-23.
17. Pankiewicz K, Kinas R, Stec WJ, Foster AB, Jarman M, van Maanen JMS (1979) Synthesis and absolute configuration assignments of enantiomeric forms of ifosphamide, sulfosphamide, and trofosphamide. J Am Chem Soc 101: 7712-7718.
18. Potrzebowski MJ, Tadeusiak E, Misiura K, Ciesielski W, Bujacz G, Tekely P (2002) A new method for distinguishing between enantiomers and racemates and assignment of enantiomeric purity by means of solid-state NMR. Examples from oxazaphos-phorinanes. Chem Eur J 8: 5007-5011.
19. Stec WJ, Radzikowski C, Szelejewski W, Kinas R, Misiura K, Grynkiewicz G, Grodner J, Kuśnierczyk H, Kutner A, Pilichowska S (1990) Pat. PL 149593.
20. Sloderbach A, Hladon B, Sochacki M, Kinas R, Kusnierczyk H, Laskowska H (1997) Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Pol J Pharmacol 49: 463-469.
21. Takamizawa A, Iwata T, Matsumoto S (1977) Studies on the urinary metabolites of isophosphamide and its activated species in rabbits. Chem Pharm Bull 25: 2900-2909.